Copyright © 1999 by the European Society of Cardiology.
Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy
a Department of Internal Medicine, Division of Cardiology, Karl-Franzens University, Graz, Austria
b Department of Internal Medicine, Division of Endocrinology and Nuclear Medicine, Karl-Franzens University, Graz, Austria
c Department of Anaesthesia, Karl-Franzens University, Graz, Austria
revised March 8, 1999; accepted March 10, 1999 1999
Abstract
Aims The degree of systolic dysfunction does not always correlate with functional impairment in patients with congestive heart failure. In contrast, diastolic dysfunction correlates well with functional impairment. In heart failure, both elevation of N-terminal proatrial natriuretic peptide and B-type natriuretic peptide are markers of a poor prognosis.
Methods We investigated 32 patients (26 male, 6 female; mean age 55±2 years) with dilated cardiomyopathy and sinus rhythm. M-mode echocardiography and 2D-echocardiography were carried out in each patient. Pulsed-wave Doppler inflow signals were obtained and the following parameters were measured: maximal E wave and maximal A wave velocity, E/A ratio, E wave deceleration time, A wave deceleration time. Immediately after echocardiography blood samples were collected from patients in the supine position. N-terminal proANP and brain natriuretic peptide were measured using a radioimmuno assay.
Results The left ventricular ejection fraction was 34±1%, the left ventricular end-diastolic diameter on M-mode echocardiography was 68±1mm, while left atrial diameter was 45±1mm. Univariate analysis revealed a significant correlation between both left atrial diameter and ejection fraction and N-terminal proANP and brain natriuretic peptide. All transmitral Doppler parameters showed a significant correlation with N-terminal proANP and brain natriuretic peptide. On forward stepwise regression analysis, left atrial diameter and ejection fraction were able to predict both N-terminal proANP and brain natriuretic peptide. However, of the diastolic parameters only the E/A ratio remained significant. Mildly symptomatic patients differed significantly from severely symptomatic patients in all Doppler parameters. Mildly symptomatic patients had significantly lower levels of N-terminal proANP (0·571±0·079 vs 2·282±0·340nmol.l–1;P<0·001) and brain natriuretic peptide (51±14·8 vs 474·2± 86·8pg.ml–1;P<0·001).
Conclusion There is a close relationship between natriuretic peptides and diastolic Doppler parameters of left ventricular filling in patients with dilated cardiomyopathy. There is also a significant difference between patients with mild and severe functional impairment regarding both natriuretic peptides and transmitral Doppler parameters.
Key Words: Idiopathic dilated cardiomyopathy, functional impairment, transmitral Doppler filling, natriuretic peptides.
f1 Correspondence: Friedrich M. Fruhwald, MD, Division of Cardiology, Department of Internal Medicine, Auenbruggerplatz 15, A-8036 Graz, Austria.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Walsh, C. Boyer, J. LaCorte, V. Parnell, C. Sison, D. Chowdhury, and K. Ojamaa N-terminal B-type natriuretic peptide levels in pediatric patients with congestive heart failure undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 98 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Codognotto, A. Piccoli, M. Zaninotto, M. Mion, M. Plebani, U. Vertolli, F. Tona, L. Ruzza, A. Barchita, and G. M. Boffa Renal Dysfunction Is a Confounder for Plasma Natriuretic Peptides in Detecting Heart Dysfunction in Uremic and Idiopathic Dilated Cardiomyopathies Clin. Chem., December 1, 2007; 53(12): 2097 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.v. Lukowicz, M. Fischer, H.W. Hense, A. Doring, J. Stritzke, G. Riegger, H. Schunkert, and A. Luchner BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy Eur J Heart Fail, June 1, 2005; 7(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hammerer-Lercher, W. Ludwig, G. Falkensammer, S. Muller, E. Neubauer, B. Puschendorf, O. Pachinger, and J. Mair Natriuretic Peptides as Markers of Mild Forms of Left Ventricular Dysfunction: Effects of Assays on Diagnostic Performance of Markers Clin. Chem., July 1, 2004; 50(7): 1174 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Troughton, D. L. Prior, J. J. Pereira, M. Martin, A. Fogarty, A. Morehead, T. G. Yandle, A. M. Richards, R. C. Starling, J. B. Young, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function J. Am. Coll. Cardiol., February 4, 2004; 43(3): 416 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F D R Hobbs, R C Davis, A K Roalfe, R Hare, M K Davies, and J E Kenkre Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations BMJ, June 22, 2002; 324(7352): 1498 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cabanes, B. Richaud-Thiriez, Y. Fulla, F. Heloire, C. Vuillemard, S. Weber, and D. Dusser Brain Natriuretic Peptide Blood Levels in the Differential Diagnosis of Dyspnea Chest, December 1, 2001; 120(6): 2047 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Amann, A. Simonaviciene, T. Medwedewa, A. Koch, S. Orth, M.-L. Gross, C. Haas, A. Kuhlmann, W. Linz, B. Scholkens, et al. Blood Pressure-Independent Additive Effects of Pharmacologic Blockade of the Renin-Angiotensin and Endothelin Systems on Progression in a Low-Renin Model of Renal Damage J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2572 - 2584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.P. Nicholls and M.S. Riley Measuring cardiac power output--the acid test Eur. Heart J., August 2, 2001; 22(16): 1368 - 1370. [PDF]
|
|
|
|
|
|
H. Oxenham and N. Sharpe Prognostic stratification in heart failure: what's the point? Eur. Heart J., November 2, 2000; 21(22): 1815 - 1816. [PDF]
|
|
|
|
|
|
A.D. Struthers Editorials: How to use natriuretic peptide levels for diagnosis and prognosis Eur. Heart J., October 1, 1999; 20(19): 1374 - 1375. [PDF]
|
|